<DOC>
	<DOC>NCT00939588</DOC>
	<brief_summary>This study is designed as a mechanistic study to compare the effect of two different combinations of anti-hypertensive treatments (aliskiren and valsartan vs. telmisartan and ramipril) on the renin-angiotensin-aldosterone system (RAAS) in patients with moderate hypertension.</brief_summary>
	<brief_title>Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Males or females of nonchildbearing potential, 18 to 65 years of age with moderate hypertension Patients who are eligible and able to participate in the study Exclusion criteria: Severe hypertension or secondary form of hypertension. Serum potassium &gt; 5.1 mEq/L (mmol/L) Heart failure Any history of hypertensive encephalopathy or cerebrovascular accident; any history of TIA, myocardial infarction, coronary bypass surgery or percutaneous coronary intervention Uncontrolled or lifethreatening arrythmia Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Aliskiren,</keyword>
	<keyword>hypertension,</keyword>
	<keyword>renin-angiotensin-aldosterone system</keyword>
</DOC>